Oxidative stress responses and NRF2 in human leukaemia

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Abdul Aziz, Amina ^a   Macewan, David J ^b   Bowles, Kristian M ^a,c   Rushworth, Stuart A ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CHEMOTHERAPY; CYTOLOGY; CYTOTOXICITY; DISEASES; OXIDATIVE STRESS; TRANSCRIPTION; TRANSCRIPTION FACTORS;

ANTIOXIDANT ENZYME; ANTIOXIDANT PROTEINS; DISEASE DEVELOPMENT; MALIGNANT TRANSFORMATIONS; NUCLEAR FACTORS; OXIDATIVE STRESS RESPONSE; REACTIVE OXYGEN SPECIES; TRANSCRIPTIONAL ACTIVATIONS;

CELLS;

REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; GLUTATHIONE;

ACUTE MYELOBLASTIC LEUKEMIA; CELL SURVIVAL; HUMAN; LEUKEMIA; ONCOGENE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; DNA DAMAGE; GENETICS; METABOLISM; PATHOLOGY;

ANTIOXIDANTS; CELL SURVIVAL; DNA DAMAGE; GLUTATHIONE; HUMANS; LEUKEMIA; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84928412324     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/454659     Document Type: Review

References (78)

1. G. Juliusson, P. Antunovic, A. Derolf et al. , "Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry," Blood, vol. 113, no. 18, pp. 4179-4187, 2009.
2. F. Buccisano, L. Maurillo, M. I. del Principe et al. , "Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia," Blood, vol. 119, no. 2, pp. 332-341, 2012.
3. K. J. Hope, L. Jin, and J. E. Dick, "Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity," Nature Immunology, vol. 5, no. 7, pp. 738-743, 2004.
4. J. M. Rowe and M. S. Tallman, "How I treat acute myeloid leukemia," Blood, vol. 116, no. 17, pp. 3147-3156, 2010.
5. H. Sies, "Oxidative stress: from basic research to clinical application," The American Journal of Medicine, vol. 91, no. 3, supplement 3, pp. S31-S38, 1991.
6. B. Halliwell, "How to characterize a biological antioxidant," Free Radical Research Communications, vol. 9, no. 1, pp. 1-32, 1990.
7. B. Halliwell, "Free radicals, proteins and DNA: oxidative damage versus redox regulation," Biochemical Society Transactions, vol. 24, no. 4, pp. 1023-1027, 1996.
8. A. M. Shah and K. M. Channon, "Free radicals and redox signalling in cardiovascular disease," Heart, vol. 90, no. 5, pp. 486-487, 2004.
9. M. Saraste, "Oxidative phosphorylation at the fin de siecle," Science, vol. 283, no. 5407, pp. 1488-1493, 1999.
10. K. J. Davies, "Oxidative stress: the paradox of aerobic life," Biochemical Society Symposium, vol. 61, pp. 1-31, 1995.
11. D. J. Reuland, J. M. McCord, and K. L. Hamilton, "The role of Nrf2 in the attenuation of cardiovascular disease," Exercise and Sport Sciences Reviews, vol. 41, no. 3, pp. 162-168, 2013.
12. S. Singh, S. Vrishni, B. K. Singh, I. Rahman, and P. Kakkar, "Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases," Free Radical Research, vol. 44, no. 11, pp. 1267-1288, 2010.
13. C. P. Ramsey, C. A. Glass, M. B. Montgomery et al. , "Expression of Nrf2 in neurodegenerative diseases," Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75-85, 2007.
14. J. E. Klaunig, Y. Xu, J. S. Isenberg et al. , "The role of oxidative stress in chemical carcinogenesis," Environmental Health Perspectives, vol. 106, supplement 1, pp. 289-295, 1998.
15. D. Ziech, R. Franco, A. Pappa, and M. I. Panayiotidis, "Reactive Oxygen Species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 711, no. 1-2, pp. 167-173, 2011.
16. A. K. Jaiswal, "Nrf2 signaling in coordinated activation of antioxidant gene expression,"FreeRadical BiologyandMedicine, vol. 36, no. 10, pp. 1199-1207, 2004.
17. K. Akashi, D. Traver, T. Miyamoto, and I. L. Weissman, "A clonogenic common myeloid progenitor that gives rise to all myeloid lineages," Nature, vol. 404, no. 6774, pp. 193-197, 2000.
18. D. G. Tenen, R. Hromas, J. D. Licht, and D.-E. Zhang, "Transcription factors, normal myeloid development, and leukemia," Blood, vol. 90, no. 2, pp. 489-519, 1997.
19. B. Lowenberg, J. R. Downing, and A. Burnett, "Acute myeloid leukemia," The New England Journal of Medicine, vol. 341, no. 14, pp. 1051-1062, 1999.
20. J. Radich, "The molecular biology of acute myeloid leukemia," in Advances in Malignant Hematology, pp. 86-102, Wiley-Blackwell, 2011.
21. F. Ishikawa, S. Yoshida, Y. Saito et al. , "Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region," Nature Biotechnology, vol. 25, no. 11, pp. 1315-1321, 2007.
22. M. S. Tallman, D. G. Gilliland, and J. M. Rowe, "Drug therapy for acutemyeloid leukemia," Blood, vol. 106, no. 4,pp. 1154-1163, 2005.
23. S. Schnittger, C. Schoch, M. Dugas et al. , "Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease," in Proceedings of the the 42nd Annual Meeting of the American Society of Hematology, vol. 100, pp. 59-66, San Francisco, Calif, USA, December 2002, abstract 3569.
24. P. Gorello, G. Cazzaniga, F. Alberti et al. , "Quantitative assessment of minimal residual disease in acutemyeloid leukemia carrying nucleophosmin (NPM1) gene mutations," Leukemia, vol. 20, no. 6, pp. 1103-1108, 2006.
25. P. D. Kottaridis, R. E. Gale, M. E. Frew et al. , "The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials," Blood, vol. 98, no. 6, pp. 1752-1759, 2001.
26. T. Kindler, D. B. Lipka, and T. Fischer, "FLT3 as a therapeutic target in AML: still challenging after all these years," Blood, vol. 116, no. 24, pp. 5089-5102, 2010.
27. A. Sallmyr, J. Fan, K. Datta et al. , "Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML," Blood, vol. 111, no. 6, pp. 3173-3182, 2008.
28. J. L. Bos, "ras Oncogenes in human cancer: a review," Cancer Research, vol. 49, no. 17, pp. 4682-4689, 1989.
29. X. Dolcet, D. Llobet, J. Pallares, and X. Matias-Guiu, "NF-kB in development and progression of human cancer," Virchows Archiv, vol. 446, no. 5, pp. 475-482, 2005.
30. A. B. Raitano, J. R. Halpern, T. M. Hambuch, and C. L. Sawyers, "The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11746-11750, 1995.
31. H. Kiyoi, T. Naoe, Y. Nakano et al. , "Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia," Blood, vol. 93, no. 9, pp. 3074-3080, 1999.
32. J. E. Roderick, J. Tesell, L. D. Shultz et al. , "c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells," Blood, vol. 123, no. 7, pp. 1040-1050, 2014.
33. M. Sattler, S. Verma, G. Shrikhande et al. , "The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells," The Journal of Biological Chemistry, vol. 275, no. 32, pp. 24273-24278, 2000.
34. J. H. Kim, S. C. Chu, J. L. Gramlich et al. , "Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species," Blood, vol. 105, no. 4, pp. 1717-1723, 2005.
35. K. Ban, Y. Gao, H. M. Amin et al. , "BCR-ABL1 mediates upregulation of Fyn in chronicmyelogenous leukemia," Blood, vol. 111, no. 5, pp. 2904-2908, 2008.
36. Y. Gao, A. Howard, K. Ban, and J. Chandra, "Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells," The Journal of Biological Chemistry, vol. 284, no. 11, pp. 7114-7125, 2009.
37. M. McMahon, K. Itoh, M. Yamamoto, and J. D. Hayes, "Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression," The Journal of Biological Chemistry, vol. 278, no. 24, pp. 21592-21600, 2003.
38. E. Kansanen, S. M. Kuosmanen, H. Leinonen, and A.-L. Levonenn, "The Keap1-Nrf2 pathway:mechanisms of activation and dysregulation in cancer," Redox Biology, vol. 1, no. 1, pp. 45-49, 2013.
39. S. A. Heasman, L. Zaitseva, K. M. Bowles, S. A. Rushworth, and D. J. MacEwan, "Protection of acute myeloid leukaemia cells fromapoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1," Oncotarget, vol. 2, no. 9, pp. 658-668, 2011.
40. S. A. Rushworth, L. Zaitseva, M. Y. Murray, N. M. Shah, K. M. Bowles, and D. J. MacEwan, "The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance," Blood, vol. 120, no. 26, pp. 5188-5198, 2012.
41. S. A. Rushworth, K. M. Bowles, and D. J. MacEwan, "High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors," Cancer Research, vol. 71, no. 5, pp. 1999-2009, 2011.
42. J. D. Hayes and M. McMahon, "NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer," Trends in Biochemical Sciences, vol. 34, no. 4, pp. 176-188, 2009.
43. B. N. Chorley, M. R. Campbell, X. Wang et al. , "Identification of novel NRF2-regulated genes by ChiP-Seq: influence on retinoid X receptor alpha," Nucleic Acids Research, vol. 40, no. 15, pp. 7416-7429, 2012.
44. Y.-S. Keum, Y.-H. Han, C. Liew et al. , "Induction of heme oxygenase-1 (HO-1) and NAD[P]H: quinone oxidoreductase 1 (NQO1) by a phenolic antioxidant, butylated hydroxyanisole (BHA) and its metabolite, tert-butylhydroquinone (tBHQ) in primary-cultured human and rat hepatocytes," Pharmaceutical Research, vol. 23, no. 11, pp. 2586-2594, 2006.
45. A. C. Wild, J. J. Gipp, and R. T. Mulcahy, "Overlapping antioxidant response element and PMA response element sequences mediate basal and β-naphthoflavone-induced expression of the human γ-glutamylcysteine synthetase catalytic subunit gene," Biochemical Journal, vol. 332, part 2, pp. 373-381, 1998.
46. A. C. Wild, H. R. Moinova, and R. T. Mulcahy, "Regulation of γ-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2," The Journal of Biological Chemistry, vol. 274, no. 47, pp. 33627-33636, 1999.
47. H. Sasaki,H. Sato, K. Kuriyama-Matsumura et al. , "Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression," The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44765-44771, 2002.
48. C. J. Harvey, R. K. Thimmulappa, A. Singh et al. , "Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress," Free Radical Biology and Medicine, vol. 46, no. 4, pp. 443-453, 2009.
49. R. P. Wu, T. Hayashi,H. B. Cottamet al. , "Nrf2 responses andthe therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia," Proceedings of the National Academy of Sciences of theUnited States of America, vol. 107, no. 16, pp. 7479-7484, 2010.
50. L. N. Barrera, S. A. Rushworth, K. M. Bowles, and D. J. MacEwan, "Bortezomib induces heme oxygenase-1 expression in multiple myeloma," Cell Cycle, vol. 11, no. 12, pp. 2248-2252, 2012.
51. P. J. Ansell, S.-C. Lo, L. G. Newton et al. , "Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha," Molecular and Cellular Endocrinology, vol. 243, no. 1-2, pp. 27-34, 2005.
52. N. Kaplowitz, T. Y. Aw, and M. Ookhtens, "The regulation of hepatic glutathione," Annual Review of Pharmacology and Toxicology, vol. 25, pp. 715-744, 1985.
53. M. J. Meredith and D. J. Reed, "Status of the mitochondrial pool of glutathione in the isolated hepatocyte," The Journal of Biological Chemistry, vol. 257, no. 7, pp. 3747-3753, 1982.
54. C. Hwang, A. J. Sinskey, and H. F. Lodish, "Oxidized redox state of glutathione in the endoplasmic reticulum," Science, vol. 257, no. 5076, pp. 1496-1502, 1992.
55. L. Yuan and N. Kaplowitz, "Glutathione in liver diseases and hepatotoxicity," Molecular Aspects of Medicine, vol. 30, no. 1-2, pp. 29-41, 2009.
56. S. C. Lu, "Regulation of hepatic glutathione synthesis: current concepts and controversies," The FASEB Journal, vol. 13, no. 10, pp. 1169-1183, 1999.
57. C. C. Franklin,D. S. Backos, I. Mohar, C. C. White,H. J. Forman, and T. J. Kavanagh, "Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase," Molecular Aspects of Medicine, vol. 30, no. 1-2, pp. 86-98, 2009.
58. W.-M. Sun, Z.-Z. Huang, and S. C. Lu, "Regulation of γ-glutamylcysteine synthetase by protein phosphorylation," Biochemical Journal, vol. 320, no. 1, pp. 321-328, 1996.
59. P. Xue, Y. Hou, Y. Chen et al. , "Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome," Diabetes, vol. 62, no. 3, pp. 845-854, 2013.
60. Y. Chen, H. G. Shertzer, S. N. Schneider, D. W. Nebert, and T. P. Dalton, "Glutamate cysteine ligase catalysis: dependence on ATP and modifier subunit for regulation of tissue glutathione levels," The Journal of Biological Chemistry, vol. 280, no. 40, pp. 33766-33774, 2005.
61. Y. Yang, M. Z. Dieter, Y. Chen, H. G. Shertzer, D. W. Nebert, and T. P. Dalton, "Initial characterization of the glutamatecysteine ligase modifier subunit Gclm(-/-) knockout mouse. Novelmodel systemfor a severely compromised oxidative stress response,"The Journal of Biological Chemistry, vol. 277, no. 51, pp. 49446-49452, 2002.
62. J. Y. Chan and M. Kwong, "Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein," Biochimica et Biophysica Acta-Gene Structure and Expression, vol. 1517, no. 1, pp. 19-26, 2000.
63. A. Singh, T. Rangasamy, R. K. Thimmulappa et al. , "Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2," The American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 6, pp. 639-650, 2006.
64. R. K. Thimmulappa, K. H. Mai, S. Srisuma, T. W. Kensler, M. Yamamoto, and S. Biswal, "Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray," Cancer Research, vol. 62,no. 18, pp. 5196-5203, 2002.
65. J. Nordberg and E. S. J. Arner, "Reactive oxygen species, antioxidants, and the mammalian thioredoxin system," Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1287-1312, 2001.
66. K. Itoh, T. Chiba, S. Takahashi et al. , "An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements," Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313-322, 1997.
67. R. N. Armstrong, "Glutathione S-transferases: reaction mechanism, structure, and function," Chemical Research in Toxicology, vol. 4, no. 2, pp. 131-140, 1991.
68. L. E. Huang, Z. Arany, D. M. Livingston, and H. F. Bunn, "Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit," Journal of Biological Chemistry, vol. 271, no. 50, pp. 32253-32259, 1996.
69. S. A. Reisman, I. I. Csanaky, L. M. Aleksunes, and C. D. Klaassen, "Altered disposition of acetaminophen in Nrf2-null and keap1-knockdown mice," Toxicological Sciences, vol. 109, no. 1, pp. 31-40, 2009.
70. X.-J. Wang, Z. Sun, N. F. Villeneuve et al. , "Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2," Carcinogenesis, vol. 29, no. 6, pp. 1235-1243, 2008.
71. S. A. Rushworth, D. J. MacEwan, and M. A. OConnell, "Lipopolysaccharide-induced expression ofNAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes," The Journal of Immunology, vol. 181, no. 10, pp. 6730-6737, 2008.
72. S. A. Rushworth and D. J. MacEwan, "HO-1 underlies resistance of AML cells to TNF-induced apoptosis," Blood, vol. 111, no. 7, pp. 3793-3801, 2008.
73. D. S. Krause, M. J. Fackler, C. I. Civin, and W. S. May, "CD34: structure, biology, and clinical utility," Blood, vol. 87, no. 1, pp. 1-13, 1996.
74. A. Blair, D. E. Hogge, and H. J. Sutherland, "Most acutemyeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLADR-," Blood, vol. 92, no. 11, pp. 4325-4335, 1998.
75. R. T. Costello, F. Mallet, B. Gaugler et al. , "Human acutemyeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities," Cancer Research, vol. 60,no. 16,pp. 4403-4411, 2000.
76. S. Pei, M. Minhajuddin, K. P. Callahan et al. , "Targeting aberrant glutathione metabolism to eradicate human acutemyelogenous leukemia cells,"The Journal of Biological Chemistry, vol. 288, no. 47, pp. 33542-33558, 2013.
77. D. Trachootham, H. Zhang, W. Zhang et al. , "Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism," Blood, vol. 112, no. 5, pp. 1912-1922, 2008.
78. M. T. Voso, F. DAlo,R. Putzuluet al. , "Negativeprognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia," Blood, vol. 100, no. 8, pp. 2703-2707, 2002.